Nicole Davarpanah named Cidara CMO

2 May 2025

Cidara Therapeutics (Nasdaq: CDTX), a San Diego biotech using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, has announced that Nicole Davarpanah has been promoted to chief medical officer (CMO).

Dr Davarpanah joined Cidara in August 2023 as senior vice president of translational research and development, having previously spent six years in rising roles of leadership at Roche (ROG: SIX) and its Genentech subsidiary, serving most recently as a clinical and translational lead, in which she was responsible for the evaluation and advancement of early-stage molecules through clinical development and US Food and Drug Administration approval.

Alongside Dr Davarpanah’s appointment, Corrina Pavetto has been promoted to senior vice president, clinical development, having joined Cidara in May 2024 as vice president of clinical development. Ms Pavetto has more than 25 years of experience in clinical research and regulatory affairs, with expertise in multiple therapeutic areas and a specialized focus on infectious disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK